MedTrace Logo

LIV001 in Patients with Mild-to-Moderate Active Ulcerative Colitis (UC)

NCT06749795 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-03-24

No results posted yet for this study

Summary

A Phase 1b study to evaluate the safety and tolerability of LIV001 in Patients with Mild-to- Moderate Active Ulcerative Colitis

Conditions

  • Ulcerative Colitis (UC)

Interventions

DRUG

LIV001

Orally administered for 8 weeks

DRUG

Placebo

Orally administered for 8 weeks

Sponsors & Collaborators

  • Liveome Inc.

    lead INDUSTRY

Principal Investigators

  • Piotr Napora, Doctor of Medicine · Centrum Badan Klinicznych Piotr Napora Lekarze Spolka Partnerska

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-24
Primary Completion
2026-01-17
Completion
2026-03-24

Countries

  • Poland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06749795 on ClinicalTrials.gov